



# Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review

Enrico Martin<sup>1,2\*</sup>, Ibtissam Acem<sup>1</sup>, Dirk J. Grünhagen<sup>1</sup>, Judith V. M. G. Bovée<sup>3</sup> and Cornelis Verhoef<sup>1</sup>

<sup>1</sup> Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, Netherlands, <sup>2</sup> Department of Plastic and Reconstructive Surgery, University Medical Center Utrecht, Utrecht, Netherlands, <sup>3</sup> Department of Pathology, Leiden University Medical Center, Leiden, Netherlands

## OPEN ACCESS

### Edited by:

Parvin Mehdipour,  
Tehran University of Medical Sciences,  
Iran

### Reviewed by:

Jilong Yang,  
Tianjin Medical University Cancer  
Institute and Hospital, China  
Jyoti Sharma,  
Institute of Bioinformatics (IOB), India

### \*Correspondence:

Enrico Martin  
e.martin-3@umcutrecht.nl

### Specialty section:

This article was submitted to  
Cancer Genetics,  
a section of the journal  
Frontiers in Oncology

**Received:** 12 August 2020

**Accepted:** 19 November 2020

**Published:** 22 December 2020

### Citation:

Martin E, Acem I, Grünhagen DJ, Bovée JVMG and Verhoef C (2020) Prognostic Significance of Immunohistochemical Markers and Genetic Alterations in Malignant Peripheral Nerve Sheath Tumors: A Systematic Review. *Front. Oncol.* 10:594069. doi: 10.3389/fonc.2020.594069

**Background:** Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with dismal prognosis. Pathological and genetic markers may predict more aggressive behavior in MPNSTs but have uncommonly been investigated, and few are used in daily practice. This study reviews the prognostic value of immunohistochemical markers and genetic alterations in MPNST.

**Methods:** A systematic search was performed in PubMed and Embase databases according to the PRISMA guidelines. Search terms related to ‘MPNST’ and ‘prognostic’ were used. Studies investigating the association of immunohistochemical markers or genetic alterations with prognosis were included. Qualitative synthesis was performed on all studies. A distinction was made between univariable and multivariable associations.

**Results:** Forty-six studies were included after full-text screening. Sixty-seven different immunohistochemical markers were investigated. Absence of S100 and H3K27me3 and high Ki67 and p53 staining was most commonly independently associated with worse survival and disease-free survival. Several genetic alterations were investigated as well with varying association to survival. *TP53*, *CDK4*, *RASSF1A* alterations were independently associated with worse survival, as well as changes in chromosomal length in Xp, 10q, and 16p.

**Conclusions:** MPNSTs harbor complex and heterogeneous biology. Immunohistochemical markers and genetic alterations have variable prognostic value. Absence of S100 and H3K27me3 and increased Ki67 can be of prognostic value. Alterations in *TP53* or increase in p53 staining may distinguish MPNSTs with worse outcomes. Genetic alterations and staining of other cell cycle regulatory and Ras pathway proteins may also help stratifying patients with worse outcomes. A combination of markers can increase the prognostic value.

**Keywords:** malignant peripheral nerve sheath tumors, prognosis, molecular, clinicopathologic, markers, genes

## INTRODUCTION

Malignant peripheral nerve sheath tumors (MPNSTs) are rare and aggressive soft tissue sarcomas (STS) that carry a dismal prognosis (1–3). Neurofibromatosis type 1 (NF1) patients have an increased risk of developing these tumors and encompass approximately 25–50% of MPNST patients (1–5). The *NF1* gene is commonly affected in MPNSTs which causes loss of the neurofibromin protein which inhibits the Ras enzyme (6). Activation of the Ras pathway leads to upregulation of the mitogen-activated protein (MAPK) and phosphoinositide 3-kinase (PI3K) pathways (7). Besides the common knockdown of *NF1*, alterations in several genes including *TP53*, *SUZ12*, *EED*, *PTEN*, and *CDKN2A* as well as upregulation of several tyrosine kinases contribute to the formation of MPNST (8–12). MPNSTs are known for harboring complex genomic alterations, but despite our increasing understanding of underlying biology, prognosis has not ameliorated the past decades and median survival stagnates at 5–6 years (2, 3).

Staging of MPNSTs is important to increase accuracy of outcome prediction, but it may also facilitate treatment stratification. However, the clinical American Joint Committee of Cancer (AJCC) STS staging system is less applicable in MPNST (4, 5, 13). The histologic Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) grading system used in STS is of prognostic value since low grade MPNST (FNCLCC grade 1) has improved survival (2). However, only 10% of MPNSTs are grade 1, and the FNCLCC grading can likely only distinguish prognosis between grades 1 and 3 (2, 5). Moreover, the histological distinction between low-grade MPNST and benign neurofibroma with atypia is difficult as objective criteria are lacking, causing interobserver variability. In the context of NF1, the diagnosis of progression to MPNST is even more challenging. Recently, a consensus view has been published defining “atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP)” as an intermediate lesion in NF1 patients (14). While driver mutations are increasingly being studied, the transition of neurofibromas to MPNSTs is not yet fully understood. Clinical parameters as predictors of outcome have been studied more commonly, but independent predictors are found inconsistently (3). Although radiation-induced MPNSTs have repeatedly been associated with worse survival, the influence of NF1 disease on survival has been subject of debate (3, 13, 15). Better classification systems for MPNSTs are therefore urgently needed.

Currently, surgery remains the only proven treatment to improve survival (1–3). Chemotherapy has limited effect in localized disease, and its use is controversial. Some studies suggest a minor benefit in high-grade, large, and deep MPNST (16–18). Moreover, 10–20% of patients present with metastatic or unresectable disease and up to 50% of patients will develop metastases over time (1–5, 13, 19). Targeted therapies are warranted, but so far none have been proven effective (20). Immunohistochemical and genetic markers may predict more aggressive behavior in MPNSTs, but their association with oncological outcome has uncommonly been investigated and few are yet used in daily practice for prognostication. For this reason this

systematic review set out to summarize current knowledge on the prognostic value of immunohistochemical and genetic markers. Such markers may enhance prognostication and aid in elucidating driver mutations of malignancy.

## METHODS

### Literature Search

A systematic search was performed in Embase and PubMed databases according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, in order to identify all potentially relevant articles as of March 2020. The string was built with the help of a professional librarian using search terms related to ‘MPNST’ and ‘prognostic’. The exact search syntaxes for PubMed and Embase are shown in **Supplementary Table 1**. Studies were included that evaluated the association of immunohistochemical markers and genetic alterations to oncological outcomes in MPNST patients. Exclusion criteria included lack of full text or studies without specific analyses fitting our inclusion criteria. The initial review was conducted by two independent authors (EM. and IA). Disagreements were solved through discussion in which one additional author was involved (CV).

### Data Extraction and Synthesis

Data extracted from studies included: study period, total number of patients, mean age and range, percentage NF1 patients, markers and genetic alterations investigated for prognostic value, and analyses used to identify prognosticators. For all markers and genetic alterations investigated additional information was extracted: number of patients with survival data, population with ‘positive’ test, oncological outcome analyzed, and whether its prognostic value was corrected for common clinical prognostic factors. Whenever the marker was independently associated with outcome, the hazard ratio was noted. Common factors for which could have been adjusted in multivariable models included: age, presence of NF1, tumor size, tumor site, metastasis at diagnosis, tumor depth, tumor grade, and surgical margin (3). All results of the predictive value of markers were presented or re-calculated to represent the marker cut-off as a negative predictor of survival. Qualitative synthesis was performed for all studies, summarizing results based on type of analysis. Immunohistochemical markers were further stratified into markers of differentiation, receptors and their ligands, Ras pathway, cell cycle regulation, p53 pathway, vascularization, and others. For each immunohistochemical marker cumulative incidence of univariable and multivariable association to survival (disease-specific or overall) or disease-free survival (recurrence, metastasis, or both) were calculated.

## RESULTS

After removal of duplicates, a total of 1,882 articles were identified in PubMed and Embase databases (**Figure 1**). Title and abstract

screening resulted in 55 potentially relevant articles, of which 46 were selected for qualitative synthesis after full-text screening. Mean age differed between 11 and 50 years old (range of all patients 1–94). Prevalence of NF1 patients in study populations ranged from 0 to 100% (mean: 48.0%). Immunohistochemical markers were studied exclusively in 36 studies, genetic alterations in seven studies, and both in three studies (**Table 1**). A total of 67 different immunohistochemical markers and numerous genetic alterations were evaluated (**Table 2, Figure 2**).

## Differentiation


Seven mesenchymal and neuronal differentiation markers were evaluated (**Table 2**), most commonly S100 (4, 45, 46, 56, 58, 62). In univariable analysis complete absence of S100 was found negatively associated with survival in four/six studies. Two studies showed the absence of S100 to be an independent predictor of worse survival with HR 4.5 (95% CI: 2.0–12.1) and HR 6.6 (95% CI: 1.8–23.8) (4, 62). All seven markers were also evaluated for association with disease-free survival (DFS). Negative S100 staining was associated with worse DFS in two/four studies, of which one study showed an independent association (HR 4.2, 95% CI: 1.5–12.3) (62). Negative smooth muscle actin (SMA) and CD57 staining were also found associated with worse DFS in univariable analysis in one study, but not in multivariable analysis (58).

## Vascularization

Microvascular density (MVD) and vascular epithelial growth factor (VEGF) staining were evaluated as vascularization markers (**Table 2**) (4, 28, 30, 57, 59). High MVD was associated with worse survival in one/four studies. This association was also significant in multivariable analyses (HR 7.3, 95% CI: 1.4–38.5) (57). High VEGF staining was associated with worse survival in one/two studies, but this was not studied in a multivariable model (59). No markers were studied for association with DFS.

## Receptors and Ligands

Immunohistochemical expression of nine different receptors or their ligands were evaluated, most commonly the epidermal growth factor receptor (EGFR, **Table 2**) (4, 29, 37–39, 55, 56, 63, 64). Increased EGFR staining was associated with worse survival in univariable analysis in two/three studies, but this was not evaluated in a multivariable model (4, 39, 54). Increased phosphorylated MET (p-MET), C-X-C motif chemokine receptor 4 (CXCR4), and low fibroblast growth factor receptor 1 (FGFR1) staining were also associated with worse survival in univariable analysis, but only p-MET (HR 1.04, 95% CI: 1.0–1.1) and FGFR1 (HR 2.8, 95% CI: 1.2–6.7) were independently associated with survival (37, 56, 63, 64). Increased EGFR and FGFR4 were associated with worse DFS, but only in univariable analyses (39, 64). On a genetic level, no amplification of *FGFR1*



**TABLE 1 |** Study characteristics of included studies.

| Author, year               | Study period | N   | Age (range) | NF1   | Markers and genetic alterations  | Analysis type <sup>a</sup> |
|----------------------------|--------------|-----|-------------|-------|--|----------------------------|
| Alaggio et al. (21)        | 1990–2007    | 35  | 11 (1–18)   | 42.9% | <i>BIRC5</i>   | RT-PCR                     |
| Benassi et al. (22)        | NA           | 17  | NA          | NA    | Laminin receptor   | IHC                        |
| Benassi et al. (23)        | NA           | 15  | NA          | NA    | MMP-2, MMP-9, TIMP-2   | IHC                        |
| Brekke et al. (24)         | 1980–2002    | 64  | 41 (13–85)  | 43.8% | p53, p-RB, CDK2, CDK4, cyclin D1, cyclin D3, cyclin E1, p14, p16, p18, p21, p27, MDM2, Ki67                              | IHC                        |
| Brekke et al. (25)         | 1980–2002    | 48  | 37 (11–79)  | 58.3% | Xq loss, 10q loss, 16p gain, 16q loss, 5p gain, 2q gain, 6q gain, 7q gain, Xp loss, 10p loss, 4q loss, 20q gain, 1q gain | aCGH                       |
| Cleven et al. (26)         | 1979–2007    | 162 | NA          | 49.4% | H3K27me3   | IHC                        |
| Danielsen et al. (27)      | 1973–2008    | 91  | 48 (11–79)  | 48.4% | <i>RASSF1A</i>   | Methylation-specific PCR   |
| Endo et al. (28)           | 1964–2008    | 99  | NA          | 33.3% | p14, p15, p16, Ki67  | IHC                        |
| Endo et al. (7)            | 1964–2010    | 88  | NA          | 40.9% | p-Akt, p-mTOR, p-S6RP, p-p70S6K, p-4E-BP1, p-MEK, p-ERK, Ki67  | IHC                        |
| Fan et al. (29)            | NA           | 56  | NA          | NA    | MET, MDM2, p53   | IHC                        |
| Fukushima et al. (30)      | 1964–2011    | 82  | NA          | 39.0% | HIF-1 $\alpha$ , HIF-2 $\alpha$ , MVD, Ki67  | IHC                        |
| Gong et al. (31)           | 2006–2015    | 14  | 46 (23–66)  | 21.4% | Ki67   | IHC                        |
| Hakozaki et al. (32)       | 1992–2008    | 44  | 50 (15–86)  | 47.7% | COX-2  | IHC                        |
| Halling et al. (33)        | NA           | 28  | 39 (15–84)  | 50.0% | p53  | IHC                        |
| Holand et al. (34)         | 1980–2010    | 100 | 36 (11–82)  | 50.0% | <i>TP53</i> , <i>MDM2</i>  | aCGH, RT-PCR               |
| Holtkamp et al. (35)       | NA           | 36  | 40 (13–78)  | 61.1% | MMP-13, p53 codon  | PCR, IHC                   |
| Holtkamp et al. (36)       | NA           | 34  | NA          | 76.5% | <i>CDKN2A</i>  | MLPA                       |
| Ikuta et al. (37)          | 1986–2011    | 30  | 45 (17–77)  | 53.3% | HA, HAS1, HAS2, HAS3   | IHC                        |
| Jia et al. (38)            | 2002–2011    | 30  | 49 (11–71)  | NA    | Decorin  | IHC                        |
| Keizman et al. (39)        | 1994–2006    | 51  | 41 (NA)     | 51.0% | EGFR   | IHC                        |
| Kobayashi et al. (40)      | 1964–2004    | 96  | 43 (0–86)   | 41.2% | CHFR, Ki67   | IHC                        |
| Kolberg et al. (41)        | 1980–2002    | 63  | 33 (13–85)  | 44.4% | Survivin, TK1, TOP2A   | IHC                        |
| Kourea et al. (42)         | NA           | 35  | NA (NA)     | NA    | p53, p-RB, p21, p27, cyclin D1, cyclin E, Ki67   | IHC                        |
| Krawczyk et al. (43)       | 1992–2013    | 26  | 10 (NA)     | 34.6% | Survivin, cyclin D1, osteopontin, fibronectin, p53   | IHC                        |
| Kresse et al. (44)         | NA           | 7   | 47 (24–78)  | NA    | 17q23.2-q25.3, <i>TOP2A</i> , <i>ETV4</i> , <i>HOXB7</i> , <i>BIRC5</i> , miR142p-3p, miR142-5p, miR201, miR21, miR338   | aCGH, RT-PCR               |
| LaFemina et al. (45)       | 1982–2011    | 105 | 38 (16–87)  | 40.0% | S100   | IHC                        |
| Le Guellec et al. (46)     | 1990–2013    | 124 | 37 (7–94)   | 54.8% | S100, MDM2, desmin   | IHC                        |
| Leroy et al. (47)          | 1988–1999    | 17  | 32 (17–56)  | 100%  | p53  | IHC                        |
| Lu et al. (48)             | 1990–2012    | 74  | 39 (11–79)  | 58.1% | ATRX   | IHC                        |
| Meis et al. (49)           | 1965–1985    | 70  | 10 (0–15)   | 20.5% | S100   | IHC                        |
| Nobeyama and Nakagawa (50) | NA           | 20  | (15–70)     | 100%  | <i>MAGEA3</i>  | Methylation-specific PCR   |
| Otsuka et al. (51)         | 1975–2016    | 145 | 48 (1–88)   | 29.7% | H3K27me3   | IHC                        |
| Panse et al. (52)          | NA           | 39  | NA          | NA    | p-STAT3  | IHC                        |
| Pekmezci et al. (53)       | 1991–2012    | 39  | 37 (11–72)  | 66.7% | H3K27me3   | IHC                        |

(Continued)

**TABLE 1 |** Continued

| Author, year                | Study period | N   | Age (range) | NF1   | Markers and genetic alterations  | Analysis type <sup>a</sup> |
|-----------------------------|--------------|-----|-------------|-------|--|----------------------------|
| Skotheim et al. (54)        | 1980–2000    | 51  | 50 (20–86)  | 37.3% | TOP2A, Ki67  | IHC                        |
| Tabone-Eglinger et al. (55) | 1985–2005    | 52  | 23 (3–60)   | 50.0% | EGFR   | IHC                        |
| Torres et al. (56)          | 1986–2006    | 96  | NA          | 57.3% | MET, HGF, p-MET, p53, S100   | IHC                        |
| de Vasconcelos et al. (57)  | 1990–2010    | 29  | NA (22–83)  | 58.6% | MCD, MVD, Ki67   | IHC                        |
| Wang et al. (58)            | 2001–2012    | 43  | 49 (NA)     | 14.0% | S100, vimentin, GFAP, NSE, Ki67, SMA, CD57   | IHC                        |
| Wasa et al. (59)            | 1987–2006    | 22  | 43 (16–83)  | 50.0% | VEGF, MVD  | IHC                        |
| Watanabe et al. (60)        | NA           | 49  | 41 (17–86)  | 44.9% | p53, Ki67, MDM2, p21   | IHC                        |
| Yu et al. (61)              | NA           | 123 | NA          | 38.2% | SOX5, NOL1, MLF2, FOXM1, FKBP4, CDK4, TSPAN31, ERBB2, MYC, TP53, SOX5, FOXM1, Myc, p53 | aCGH, RT-PCR, FISH, IHC    |
| Yuan et al. (62)            | 1999–2016    | 159 | 40 (5–76)   | 44.0% | S100, Ki67, vimentin, NF, GFAP   | IHC                        |
| Zhang et al. (63)           | 1991–2011    | 58  | 47 (6–86)   | 0.0%  | CXCR4, CXCL12, cyclin D1   | IHC                        |
| Zhou et al. (64)            | NA           | 63  | NA          | NA    | FGFR1, FGFR2, FGFR4, FGFR1   | FISH, IHC                  |
| Zou et al. (4)              | 1986–2006    | 140 | 35 (1–80)   | 51.4% | S100, Ki67, p53, VEGF, EGFR, p-MEK   | IHC                        |

<sup>a</sup>Used for correlation with outcome.

4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; aCGH, array-based comparative genomic hybridization; CDK, cyclin dependant kinase; CHFR, checkpoint with forkhead-associated domain and ring finger; COX-2, cyclooxygenase-2; CXCR4, C-X-C motif chemokine receptor 4; CXCL12, C-X-C motif chemokine ligand 12; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinases; FISH, fluorescence in situ hybridization; FGFR, fibroblast growth factor receptor; FOXM1, forkhead box protein M1; GFAP, glial fibrillary acidic protein; H3K27me3, trimethylation of lysine 27 of histone H3; HA, hyaluronan; HAS, hyaluronan synthase; HIF, hypoxia-inducible factor; IHC, immunohistochemistry; MCD, mast cell density; MDM2, mouse double minute 2 homolog; MEK, mitogen-activated protein kinase kinase; Met, metastasis; MLPA, multiplex ligation-dependent probe amplification; MMP-13, matrix metalloproteinase 13; mTOR, mammalian target of rapamycin; MVD, microvessel density; N, total number of patients; NA, not available; NF1, neurofibromatosis type 1p-, phosphorylated; RASSF1A, Ras association domain family member 1, isoform A; RT-PCR, reverse transcription polymerase chain reaction; S6RP, ribosomal protein S6; SMA, smooth muscle actin; STAT3, Signal transducer and activator of transcription 3; TIMP-2, tissue inhibitor of metalloproteinase 2; TK1, thymidine kinase 1; TOP2A, topoisomerase 2-alpha; VEGF, vascular endothelial growth factor.

**TABLE 2 |** Prognostic value of immunohistochemical markers.

| Marker                       | N | Survival <sup>a</sup> |      |              |      | N | Disease-free survival <sup>a</sup> |      |              |      |
|------------------------------|---|-----------------------|------|--------------|------|---|------------------------------------|------|--------------|------|
|                              |   | Univariate            |      | Multivariate |      |   | Univariate                         |      | Multivariate |      |
|                              |   | +                     | NA   | +            | -    |   | +                                  | NA   | +            | -    |
| <i>Differentiation</i>       |   |                       |      |              |      |   |                                    |      |              |      |
| S100                         | 7 | 57%                   | 25%  | 50%          | 25%  | 4 | 50%                                | 50%  | 50%          | 0%   |
| GFAP                         | 2 | 0%                    | NA   | NA           | NA   | 2 | 0%                                 | NA   | NA           | NA   |
| Vimentin                     | 2 | 0%                    | NA   | NA           | NA   | 2 | 0%                                 | NA   | NA           | NA   |
| NSE                          | 1 | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| SMA                          | 1 | 0%                    | NA   | NA           | NA   | 1 | 100%                               | 0%   | 0%           | 100% |
| Desmin                       | 1 | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| CD57                         | 1 | 0%                    | NA   | NA           | NA   | 1 | 100%                               | 0%   | 0%           | 100% |
| <i>Vascularization</i>       |   |                       |      |              |      |   |                                    |      |              |      |
| MVD                          | 4 | 25%                   | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| VEGF                         | 2 | 50%                   | 100% | 0%           | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| <i>Receptors and ligands</i> |   |                       |      |              |      |   |                                    |      |              |      |
| EGFR                         | 3 | 67%                   | 100% | 0%           | 0%   | 1 | 100%                               | 100% | 0%           | 0%   |
| MET                          | 2 | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| p-MET                        | 1 | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| HGF                          | 1 | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| CXCR4                        | 1 | 100%                  | 0%   | 0%           | 100% | 1 | 0%                                 | NA   | NA           | NA   |
| CXCL12                       | 1 | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| FGFR1                        | 1 | 100%                  | 0%   | 100%         | 0%   | 1 | 0%                                 | NA   | NA           | NA   |
| FGFR2                        | 1 | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |

(Continued)

TABLE 2 | Continued

| Marker                       | N  | Survival <sup>a</sup> |      |              |      | N | Disease-free survival <sup>a</sup> |      |              |      |
|------------------------------|----|-----------------------|------|--------------|------|---|------------------------------------|------|--------------|------|
|                              |    | Univariate            |      | Multivariate |      |   | Univariate                         |      | Multivariate |      |
|                              |    | +                     | NSA  | +            | -    |   | +                                  | NA   | +            | -    |
| FGFR4                        | 1  | 0%                    | NA   | NA           | NA   | 1 | 100%                               | 0%   | 0%           | 100% |
| HA                           | 1  | 100%                  | 0%   | 0%           | 100% | 1 | 100%                               | 0%   | 100%         | 0%   |
| HAS1                         | 1  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| HAS2                         | 1  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| HAS3                         | 1  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| Decorin                      | 1  | 100%                  | 100% | 0%           | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| <i>Ras pathway</i>           |    |                       |      |              |      |   |                                    |      |              |      |
| p-MEK                        | 2  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| NF                           | 1  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| p-ERK                        | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| p-Akt                        | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| p-mTOR                       | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| p-p70S6K                     | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| p-4E-BP1                     | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| p-S6RP                       | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| COX-2                        | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| Myc                          | 1  | 100%                  | 0%   | 0%           | 100% | 0 | NA                                 | NA   | NA           | NA   |
| <i>Cell cycle regulation</i> |    |                       |      |              |      |   |                                    |      |              |      |
| p53                          | 10 | 40%                   | 25%  | 75%          | 0%   | 3 | 67%                                | 50%  | 50%          | 0%   |
| MDM2                         | 4  | 0%                    | NA   | NA           | NA   | 2 | 50%                                | 100% | 0%           | 0%   |
| Cyclin D1                    | 4  | 25%                   | 0%   | 100%         | 0%   | 3 | 33%                                | 0%   | 100%         | 0%   |
| p21                          | 3  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| Cyclin E                     | 2  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| p-RB                         | 2  | 0%                    | NA   | NA           | NA   | 1 | 100%                               | 100% | 0%           | 0%   |
| p14                          | 2  | 100%                  | 0%   | 50%          | 50%  | 0 | NA                                 | NA   | NA           | NA   |
| p16                          | 2  | 50%                   | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| p27                          | 2  | 50%                   | 100% | 0%           | 0%   | 1 | 0%                                 | NA   | NA           | NA   |
| p15                          | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| p18                          | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| FOXM1                        | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| SOX5                         | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| CDK2                         | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| CDK4                         | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| Cyclin D3                    | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| HIF1 $\alpha$                | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| HIF2 $\alpha$                | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| CHFR                         | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| <i>Epigenetic modulation</i> |    |                       |      |              |      |   |                                    |      |              |      |
| H3K27me3                     | 3  | 67%                   | 0%   | 50%          | 50%  | 1 | 0%                                 | NA   | NA           | NA   |
| TOP2A                        | 2  | 100%                  | 50%  | 0%           | 50%  | 1 | 100%                               | 100% | 0%           | 0%   |
| <i>Other</i>                 |    |                       |      |              |      |   |                                    |      |              |      |
| Ki67                         | 13 | 62%                   | 0%   | 25%          | 75%  | 5 | 40%                                | 0%   | 50%          | 50%  |
| Survivin                     | 2  | 50%                   | 0%   | 0%           | 100% | 1 | 0%                                 | NA   | NA           | NA   |
| ATRX                         | 1  | 100%                  | 0%   | 100%         | 0%   | 0 | NA                                 | NA   | NA           | NA   |
| TK1                          | 1  | 100%                  | 0%   | 0%           | 100% | 0 | NA                                 | NA   | NA           | NA   |
| MCD                          | 1  | 0%                    | NA   | NA           | NA   | 0 | NA                                 | NA   | NA           | NA   |
| p-STAT3                      | 1  | 100%                  | 100% | 0%           | 0%   | 1 | 0%                                 | NA   | NA           | NA   |
| Osteopontin                  | 1  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| Fibronectin                  | 1  | 0%                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| MMP-2                        | 0  | NA                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| MMP-9                        | 0  | NA                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| MMP-13                       | 0  | NA                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| TIMP-2                       | 0  | NA                    | NA   | NA           | NA   | 1 | 0%                                 | NA   | NA           | NA   |
| Laminin receptor             | 0  | NA                    | NA   | NA           | NA   | 1 | 100%                               | 100% | NA           | NA   |

<sup>a</sup>Univariate analysis: significant effect (+), not significant effect (-); Multivariate analysis: not performed (NA), significant effect (+), not significant effect (-).

4E-BP1, eukaryotic translation initiation factor 4E-binding protein 1; CDK, cyclin dependent kinase; CHFR, checkpoint with forkhead-associated domain and ring finger; COX-2, cyclooxygenase-2; CXCR4, C-X-C motif chemokine receptor 4; CXCL12, C-X-C motif chemokine ligand 12; DFS, disease-free survival (either time to recurrence, metastasis, or both); EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinases; FGFR, fibroblast growth factor receptor; FOXM1, forkhead box protein M1; GFAP, glial fibrillary acidic protein; H3K27me3, trimethylation of lysine 27 of histone H3; HA, hyaluronan; HAS, hyaluronan synthase; HIF, hypoxia-inducible factor; MCD, mast cell density; MDM2, mouse double minute 2 homolog; MEK, mitogen-activated protein kinase kinase; MMP, matrix metalloproteinase; mTOR, mammalian target of rapamycin; MVD, microvessel density; N, number of studies; NA, not applicable; NF, neurofibromin; p-, phosphorylated; S, survival (either disease-specific or overall); S6RP, ribosomal protein S6; SMA, smooth muscle actin; STAT3, Signal transducer and activator of transcription 3; TIMP-2, tissue inhibitor of metalloproteinase 2; TK1, thymidine kinase 1, TOP2A, topoisomerase 2-alpha; VEGF, vascular endothelial growth factor.



amplification on FISH of *CDK4* was associated with worse survival (34, 61). Gain (HR 4.2, 95% CI: 1.4–12.4) or amplification (HR 2.0, 95% CI: 1.0–4.0) of *CDK4* was independently associated with worse survival (59). The combination of either *MDM2* gain or *TP53* aberration made a high risk group (16%) for worse survival with a HR 3.4 (95% CI: 1.4–8.3) (34). In the same study, a gene expression profile was made and a score of  $\geq 0.12$  was present in 66.7% of the population which was associated with worse survival as well (HR 4.0, 95% CI: 1.3–12.1). Another study on DNA copy number changes found a significant association with worse survival for gain at 17q23.2–25.3, but not in several related genes or micro-RNAs in this region (44). The association was not evaluated in a multivariable model. A gain in *FOXMI* was worse survival in another study (61). Only the polymorphism of p53Pro<sup>72</sup> was associated with worse DFS in one study (35). This association was not evaluated in a multivariable model.

## Epigenetic Modulation

Two epigenetic modulating proteins were investigated as immunohistochemical markers (**Table 2**) (26, 41, 51, 53, 54). Loss of trimethylation of lysine 27 of histone H3 (H3K27me3) and increased topoisomerase 2-alpha (TOP2A) staining were both associated with decreased survival (26, 41, 51, 54). Only H3K27me3 was independently associated with worse survival (HR 2.6, 95% CI: 1.2–5.7) in one out of two studies (26, 51). Increased TOP2A staining was also associated with worse DFS in one study (54). High copy number changes of *TOP2A* was not associated with worse survival (**Supplementary Table 2**) (44).

## Other

Thirteen other immunohistochemical markers were studied, most commonly the proliferation marker Ki67 (4, 7, 24, 30, 31, 40–43, 48, 52, 54, 57, 58, 60–62). On average a cut-off at 20.9% (range: 5–30%) for high Ki67 staining was used and it was significantly associated with worse survival in 8/12 studies, of which two studies showed an independent association (HR 2.4, 95% CI: 1.1–4.9 and HR 10.2, 95% CI: 3.6–32.1) (28, 30). Increased survivin, thymidine kinase 1 (TK1), phosphorylated signal transducer and activator of transcription 3 (p-STAT3), and hypoxia-induced factor 1-alpha (HIF1 $\alpha$ ) and decreased ATRX staining were associated with worse survival (30, 41, 48). Both decreased ATRX (HR 5.3, 95% CI: 1.4–20.4) and positive HIF1 $\alpha$  staining (HR 8.3, 95% CI: 2.8–28.9) were independently associated with worse survival (30, 48). One study showed that when there was high survivin and high TK1 staining or low survivin and high TOP2A staining a high risk group of patients could be stratified with HR 4.6 (95% CI: 1.5–14.4) (41). Increased staining of Ki67 and laminin receptor were associated with worse DFS (22, 31, 62). Only high Ki67 staining was shown to have an independent association with worse DFS in one/two studies (HR 3.8, 95% CI: 1.7–8.5) (62). Four studies investigated several other genetic alterations, including two on *BIRC5*, the gene encoding surviving (21, 25, 44, 50). One out of two studies showed that an increase in *BIRC5* mRNA was associated with worse survival in univariable analysis (21). Gain at 17q23.2–25.3 was associated with worse survival in

univariable analysis in another study (44). One study investigated the effect of chromosomal gains and losses and showed an independent effect on worse survival for Xq loss (HR 3.6, 95% CI: 1.6–8.3), 10q loss (HR 3.2, 95% CI: 1.4–7.7), and 16p gain (HR 2.5, 95% CI: 1.0–6.2) (25). Together a high risk group (63% of population) was obtained for either gain or loss which resulted in a HR 11.0 (95% CI: 3.5–35.0) after correction for several clinical characteristics. A gain in *SOX5* and *NOL1* were associated with worse survival in one study, but only in univariable analyses (61). Finally, methylation of *MAGEA3* was also associated with worse survival in univariable analysis (50).

## DISCUSSION

The underlying biology of MPNSTs remains complex as is highlighted by the diverse findings of studies included in this review. Many markers and genetic alterations have been proposed to be of prognostic value, yet outcomes are infrequently repeated. Alterations in *TP53* or its resulting increased p53 staining were commonly found associated with survival and DFS as were several other proteins and genes involved in cell cycle regulation. Epigenetic modulatory proteins, especially loss of H3K27me3, and more general markers as absence of S100 and increased Ki67 were commonly found to be of prognostic value too.

## Prognostication in MPNST

The predictive value of clinical parameters including patient and tumor characteristics has been studied more commonly than immunohistochemical or genetic biomarkers in MPNST. Increasing age, large tumor size, metastatic disease at diagnosis, and tumors not amenable to complete resection are the most commonly found predictors of worse survival in MPNST (2, 3, 5, 13, 45, 65). This emphasizes the importance of early diagnosis of MPNST in order to completely resect tumors, along with finding new systemic therapies to improve the prognosis of irresectable and metastatic disease. Non-extremity tumor sites have also been shown to have a negative impact on survival; however, this may be more true for those arising in retroperitoneal or pelvic sites (1, 3, 5, 13, 66). Tumor depth used to be incorporated for prognostication in the AJCC staging system for STS, but has varying been shown to be of prognostic value in MPNST (2, 3, 5, 13, 45, 65). The importance of NF1 disease has also been subject of debate. A meta-analysis in 2012 showed no difference in survival for patients in papers published after 2000 (15). However, recent large cohorts did find an independent association with worse survival for NF1 patients (3, 13, 67, 68). Altogether, clinical parameters seem to be able to predict some part of a patient's course of disease. The addition of tumor biology to clinical parameters may further increase our ability to stratify subgroups of patients based on prognosis. *TP53* is one of the few recurrently mutated genes found in MPNST. *TP53* mutations and high p53 staining were independently associated with survival or DFS in five different studies (4, 24, 34, 43, 56). This may indicate that aberrations in this gene may indeed be of clinical importance. Other genes involved in cell cycle regulation such as *CDKN2A* and downstream proteins are commonly altered and may not only contribute to tumorigenesis but also be of clinical significance,



supporting a belief that dysregulations in this cellular pathway are of overall importance. Loss of polycomb repressive complex 2 (PRC2) complex has recently been shown to be common in MPNSTs due to mutations in *EED* and *SUZ12* (9, 69). This results in loss of H3K27me3 which can reliably distinguish high-grade MPNSTs from their benign counterparts by immunohistochemistry (26, 70). MPNSTs without loss of H3K27me3 staining may also be associated with less aggressive behavior as many low-grade MPNSTs are known to retain this expression (14, 26). Preclinical research on targeted therapies has most frequently shown promising results targeting proteins in the Ras pathway, especially when combined with other target drugs, but unfortunately no clinical trial has proven benefit to date (20). Activated proteins in the Ras pathway, including p-mTOR, p-4E-BP1, p-S6RP, COX-2, and Myc as well as methylation of *RASSF1A* may however predict worse survival (6, 7, 27, 32). Targeting vascular pathways in MPNSTs may be beneficial, but unfortunately few studies have focused on this. Studies included in this review also showed that increased vascularity, as evidenced by increased microvascular density as well as increased expression of VEGF, may be associated with more aggressive biological behavior (57, 59). It seems that many other targets may be of prognostic value as well emphasizing the need for further research into MPNST tumor biology. Survivin markers may for instance stratify a subgroup of patients and survivin has been shown a viable target in a xenograft mouse model (71). Seeing as MPNSTs are heterogenic and markers such as p53 are not MPNST specific, combined scores of different markers and genetic alterations may be of most clinical importance. Four studies in this review highlight this phenomenon demonstrating increased prognostic value when markers are combined (25, 28, 34, 41).

## Strengths and Limitations

Unfortunately, due to the large heterogeneity of published studies meta-analyses were not presumed feasible. All studies included in this review were retrospective of nature inherently harboring bias. None of the markers and genetic alterations found in these studies were prospectively validated. Moreover, many did not evaluate the prognostic value of their markers in a multivariable model nor on their discriminative ability. Studies that evaluated the prognostic value of markers in a multivariable model were nonetheless not always capable to correct for all common clinical variables. MPNSTs are rare sarcomas, which in combination with their complex biology, make it difficult to obtain enough cases to create valuable models. But as shown in this review, several markers and genetic alterations may already be of clinical importance as they have shown an independent association with survival in addition to clinical parameters. Future research should therefore be encouraged to replicate these results using larger datasets obtained by large-scale international collaborations. Important immunohistochemical

staining may include Ki67, S100, p53, and H3K27me3 in all patients, and possibly further staining of proteins associated with cell cycle regulation. In turn individual prediction models for MPNST patients specifically may arise taking their significant heterogeneity into account. Such models may better elucidate patient selection for (neo)adjuvant treatment and targeted therapies, which should then be validated in a prospective database. But as MPNSTs remain rare entities one may also turn to exploratory analyses using machine learning techniques on large STS genetic databases to identify attractive genes as biomarkers or prognostic markers in subtypes of STS (72).

## CONCLUSION

MPNSTs harbor complex and heterogenic biology and currently lack adequate staging systems. Immunohistochemical markers and genetic alterations are varying of prognostic value. Absence of S100 and H3K27me3 and increased Ki67 staining were commonly found to be of independent prognostic value alongside of clinical parameters. Alterations in *TP53* or its consequential increase in p53 staining seems to distinguish a subgroup of MPNSTs with worse outcomes. Immunohistochemical staining and associated genetic alterations of proteins involved in cell cycle regulation and the Ras pathway may also help stratifying patients with worse outcomes. Other markers will likely need further evaluation for validation. A combination of markers may increase the prognostic value.

## DATA AVAILABILITY STATEMENT

All datasets presented in this study are included in the article/**Supplementary Material**.

## AUTHOR CONTRIBUTIONS

Study conceptualization: EM, CV. Study design: EM, IA, DG, JB, CV. Data acquisition: EM, IA. Drafting manuscript: EM, IA. Study supervision: DG, JB, CV. Manuscript reviewing: DG, JB, CV. Approval of final manuscript: EM, IA, DG, JB, CV. All authors contributed to the article and approved the submitted version.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fonc.2020.594069/full#supplementary-material>

## REFERENCES

1. Stucky C-CH, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. *Ann Surg Oncol* (2012) 19:878–85. doi: 10.1245/s10434-011-1978-7
2. Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath

- tumors: The experience of the French Sarcoma Group (GSF-GETO). *Eur J Cancer* (2016) 56:77–84. doi: 10.1016/j.ejca.2015.12.015
3. Martin E, Coert JH, Flucke UE, Slooff W-BM, Ho VKY, van der Graaf WT, et al. A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours. *Eur J Cancer* (2019) 124:77–87. doi: 10.1016/j.ejca.2019.10.014
  4. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang W-L, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. *Ann Surg* (2009) 249:1014–22. doi: 10.1097/SLA.0b013e3181a77e9a
  5. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* (2006) 107:1065–74. doi: 10.1002/cncr.22098
  6. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. *Nature* (1992) 356:713–5. doi: 10.1038/356713a0
  7. Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. *Clin Cancer Res* (2013) 19:450–61. doi: 10.1158/1078-0432.CCR-12-1067
  8. Beert E, Brems H, Daniels B, De Wever I, Van Calenbergh F, Schoenaers J, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. *Genes Chromosomes Cancer* (2011) 50:1021–32. doi: 10.1002/gcc.20921
  9. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. *Nature* (2014) 514:247–51. doi: 10.1038/nature13561
  10. Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, et al. TP53 mutations are frequent in malignant NF1 tumors. *Genes Chromosomes Cancer* (1994) 10:250–5. doi: 10.1002/gcc.2870100405
  11. Masliah-Planchon J, Pasmant E, Luscan A, Laurendeau I, Ortonne N, Hivelin M, et al. MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. *BMC Genomics* (2013) 14:473. doi: 10.1186/1471-2164-14-473
  12. Kluewe L, Friedrich RE, Mautner VF. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. *Cancer Genet Cytogenet* (1999) 113:65–9. doi: 10.1016/S0165-4608(99)00006-0
  13. Miao R, Wang H, Jacobson A, Lietz AP, Choy E, Raskin KA, et al. Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST. *Radiother Oncol* (2019) 137:61–70. doi: 10.1016/j.radonc.2019.03.015
  14. Miettinen MM, Antonescu CR, Fletcher CDM, Kim A, Lazar AJ, Quezado MM, et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. *Hum Pathol* (2017) 67:1–10. doi: 10.1016/j.humpath.2017.05.010
  15. Kolberg M, Holand M, Agesen TH, Brekke HR, Liestol K, Hall KS, et al. Survival meta-analysis for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. *Neuro Oncol* (2013) 15:135–47. doi: 10.1093/neuonc/nos287
  16. Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncol* (2017) 18:812–22. doi: 10.1016/S1470-2045(17)30334-0
  17. Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. *Sarcoma* (2017) 2017:8685638. doi: 10.1155/2017/8685638
  18. Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. *J Clin Oncol* (2005) 23:8422–30. doi: 10.1200/JCO.2005.01.4886
  19. Zehou O, Bularca S, Bastuji-Garin S, Ortonne N, Valeyrie-Allanore L, Wolkenstein P, et al. Neurofibromatosis 1 phenotype associated to malignant peripheral nerve sheath tumours: A case-control study. *J Eur Acad Dermatol Venereol* (2013) 27:1044–7. doi: 10.1111/j.1468-3083.2012.04485.x
  20. Martin E, Lamba N, Flucke UE, Verhoef C, Coert JH, Versleijen-Jonkers YMH, et al. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside. *Crit Rev Oncol Hematol* (2019) 138:223–32. doi: 10.1016/j.critrevonc.2019.04.007
  21. Alaggio R, Turrini R, Boldrin D, Merlo A, Gambini C, Ferrari A, et al. Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). *PLoS One* (2013) 8:e80456. doi: 10.1371/journal.pone.0080456
  22. Benassi MS, Ragazzini P, Gamberi G, Sollazzo MR, Molendini L, Ferrari C, et al. Adhesion molecules in high-grade soft tissue sarcomas: Correlation to clinical outcome. *Eur J Cancer* (1998) 34:496–502. doi: 10.1016/S0959-8049(97)10097-1
  23. Benassi MS, Gamberi G, Magagnoli G, Molendini L, Ragazzini P, Merli M, et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. *Ann Oncol* (2001) 12:75–80. doi: 10.1023/A:1008318614461
  24. Brekke HR, Kolberg M, Skotheim RI, Hall KS, Bjerkehagen B, Risberg B, et al. Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. *Neuro Oncol* (2009) 11:514–28. doi: 10.1215/15228517-2008-127
  25. Brekke HR, Ribeiro FR, Kolberg M, Ågesen TH, Lind GE, Eknæs M, et al. Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. *J Clin Oncol* (2010) 28:1573–82. doi: 10.1200/JCO.2009.24.899
  26. Cleven AHG, Sanna GAA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. *Mod Pathol* (2016) 29:582–90. doi: 10.1038/modpathol.2016.45
  27. Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Hall KS, et al. Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. *Neuro Oncol* (2015) 17:63–9. doi: 10.1093/neuonc/nou140
  28. Endo M, Kobayashi C, Setsu N, Takahashi Y, Kohashi K, Yamamoto H, et al. Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. *Clin Cancer Res* (2011) 17:3771–82. doi: 10.1158/1078-0432.CCR-10-2393
  29. Fan Q, Yang J, Wang G. Clinical and molecular prognostic predictors of malignant peripheral nerve sheath tumor. *Clin Transl Oncol* (2014) 16:191–9. doi: 10.1007/s12094-013-1061-x
  30. Fukushima S, Endo M, Matsumoto Y, Fukushi JI, Matsunobu T, Kawaguchi KI, et al. Potential therapeutic target in malignant peripheral nerve sheath tumor. *PLoS One* (2017) 12:e0178064. doi: 10.1371/journal.pone.0178064
  31. Gong H, Zhang D, Wang D, He S, Yang X, Wei H, et al. Benign-appearing intraspinal malignant peripheral nerve sheath tumors: Treatments and outcomes of 14 consecutive patients. *Turk Neurosurg* (2018) 28:983–8. doi: 10.5137/1019-5149.JTN.22580-18.1
  32. Hakozaiki M, Tajino T, Konno S, Kikuchi S, Yamada H, Yanagisawa M, et al. Overexpression of cyclooxygenase-2 in malignant peripheral nerve sheath tumor and selective cyclooxygenase-2 inhibitor-induced apoptosis by activating caspases in human malignant peripheral nerve sheath tumor cells. *PLoS One* (2014) 9:e88035. doi: 10.1371/journal.pone.0088035
  33. Halling KC, Scheithauer BW, Halling AC, Nascimento AG, Ziesmer SC, Roche PC, et al. p53 Expression in neurofibroma and malignant peripheral nerve sheath tumor: An immunohistochemical study of sporadic and NF1-associated tumors. *Am J Clin Pathol* (1996) 106:282–8. doi: 10.1093/ajcp/106.3.282
  34. Holand M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, et al. Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53. *Mod Pathol* (2018) 31:1694–707. doi: 10.1038/s41379-018-0074-y
  35. Holtkamp N, Atallah I, Okuducu A-F, Mucha J, Hartmann C, Mautner V-F, et al. MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. *Neoplasia* (2007) 9:671–7. doi: 10.1593/neo.07304
  36. Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. *Neuro Oncol* (2008) 10:946–57. doi: 10.1215/15228517-2008-053
  37. Ikuta K, Urakawa H, Kozawa E, Arai E, Zhuo L, Futamura N, et al. Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors. *Clin Exp Metastasis* (2014) 31:715–25. doi: 10.1007/s10585-014-9662-5
  38. Jia X, Chen C, Chen L, Yu C, Kondo T. Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors. *Oncol Lett* (2019) 17:3517–22. doi: 10.3892/ol.2019.9959

39. Keizman D, Issakov J, Meller I, Meimon N, Ish-Shalom M, Sher O, et al. Expression and significance of EGFR in malignant peripheral nerve sheath tumor. *J Neurooncol* (2009) 94:383–8. doi: 10.1007/s11060-009-9862-z
40. Kobayashi C, Oda Y, Takahira T, Izumi T, Kawaguchi K, Yamamoto H, et al. Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. *Mod Pathol* (2006) 19:524–32. doi: 10.1038/modpathol.3800548
41. Kolberg M, Holand M, Lind GE, Agesen TH, Skotheim RI, Hall KS, et al. Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours—A prognostic test after surgical resection. *Mol Oncol* (2015) 9:1129–39. doi: 10.1016/j.molonc.2015.02.005
42. Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM. Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: The emerging role of p27(kip) in malignant transformation of neurofibromas. *Am J Pathol* (1999) 155:1885–91. doi: 10.1016/S0002-9440(10)65508-3
43. Krawczyk MA, Karpinsky G, Izycka-Swieszevska E, Gabrych A, Kunc M, Fatyga A, et al. Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. *Cancer Biomark* (2019) 24:351–61. doi: 10.3233/CBM-181572
44. Kresse SH, Skårn M, Ohnstad HO, Namlos HM, Bjerkehagen B, Myklebost O, et al. DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. *Mol Cancer* (2008) 7. doi: 10.1186/1476-4598-7-48
45. LaFemina J, Qin L-X, Moraco NH, Antonescu CR, Fields RC, Crago AM, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. *Ann Surg Oncol* (2013) 20:66–72. doi: 10.1245/s10434-012-2573-2
46. Le Guellec S, Decouvelaere A-V, Filleron T, Valo I, Charon-Barra C, Robin Y-M, et al. Malignant Peripheral Nerve Sheath Tumor Is a Challenging Diagnosis: A Systematic Pathology Review, Immunohistochemistry, and Molecular Analysis in 160 Patients From the French Sarcoma Group Database. *Am J Surg Pathol* (2016) 40:896–908. doi: 10.1097/PAS.0000000000000655
47. Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler J, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. *Arch Dermatol* (2001) 137:908–13.
48. Lu H-C, Eulo V, Apicelli AJ, Pekmezci M, Tao Y, Luo J, et al. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. *Oncotarget* (2018) 9:23018–28. doi: 10.18632/oncotarget.25195
49. Meis JM, Enzinger FM, Martz KL, Neal JA. Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. *Am J Surg Pathol* (1992) 16:694–707. doi: 10.1097/00000478-199207000-00008
50. Nobeyama Y, Nakagawa H. Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. *J Dermatol Sci* (2016) 81:118–23. doi: 10.1016/j.jdermsci.2015.11.004
51. Otsuka H, Kohashi K, Yoshimoto M, Ishihara S, Toda Y, Yamada Y, et al. Immunohistochemical evaluation of H3K27 trimethylation in malignant peripheral nerve sheath tumors. *Pathol Res Pract* (2018) 214:417–25. doi: 10.1016/j.prp.2017.12.015
52. Panse G, Leung CH, Ingram DR, Wani K, Torres KE, Lin H, et al. The role of phosphorylated signal transducer and activator of transcription 3 (pSTAT3) in peripheral nerve sheath tumours. *Histopathology* (2017) 70:946–53. doi: 10.1111/his.13154
53. Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. *Mod Pathol* (2017) 30:1710–9. doi: 10.1038/modpathol.2017.97
54. Skotheim RI, Kallioniemi A, Bjerkehagen B, Mertens F, Brekke HR, Monni O, et al. Topoisomerase-II $\alpha$  is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. *J Clin Oncol* (2003) 21:4586–91. doi: 10.1200/JCO.2003.07.067
55. Tabone-Eglinger S, Bahleda R, Côté J-F, Terrier P, Vidaud D, Cayre A, et al. Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. *Sarcoma* (2008) 2008:1–7. doi: 10.1155/2008/849156
56. Torres KE, Zhu Q-S, Bill K, Lopez G, Ghadimi MP, Xie X, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. *Clin Cancer Res* (2011) 17:3943–55. doi: 10.1158/1078-0432.CCR-11-0193
57. de Vasconcelos RAT, Guimarães Coscarelli P, Vieira TM, Nogueira WS, Rapozo DCM, Acioly MA. Prognostic significance of mast cell and microvascular densities in malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. *Cancer Med* (2019) 8:972–81. doi: 10.1002/cam4.1977
58. Wang T, Yin H, Han S, Yang X, Wang J, Huang Q, et al. Malignant peripheral nerve sheath tumor (MPNST) in the spine: a retrospective analysis of clinical and molecular prognostic factors. *J Neurooncol* (2015) 122:349–55. doi: 10.1007/s11060-015-1721-5
59. Wasa J, Nishida Y, Suzuki Y, Tsukushi S, Shido Y, Hosono K, et al. Differential expression of angiogenic factors in peripheral nerve sheath tumors. *Clin Exp Metastasis* (2008) 25:819–25. doi: 10.1007/s10585-008-9197-8
60. Watanabe T, Oda Y, Tamiya S, Kinukawa N, Masuda K, Tsuneyoshi M. Malignant peripheral nerve sheath tumours: High Ki67 labelling index is the significant prognostic indicator. *Histopathology* (2001) 39:187–97. doi: 10.1046/j.1365-2559.2001.01176.x
61. Yu J, Deshmukh H, Payton JE, Dunham C, Scheithauer BW, Tihan T, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. *Clin Cancer Res* (2011) 17:1924–34. doi: 10.1158/1078-0432.CCR-10-1551
62. Yuan ZN, Xu LB, Zhao ZG, Xu SF, Zhang XX, Liu T, et al. Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. *Oncotarget* (2017) 8:104785–95. doi: 10.18632/oncotarget.18975
63. Zhang C, Chang F-Y, Zhou W-Y, Yang J-L. The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors. *Chin J Cancer* (2017) 36:1–8. doi: 10.1186/s40880-017-0246-z
64. Zhou W, Du X, Song F, Zheng H, Chen K, Zhang W, et al. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor. *Oncotarget* (2016) 7:22234–44. doi: 10.18632/oncotarget.8067
65. Watson KL, Al Sanna GA, Kivlin CM, Ingram DR, Landers SM, Roland CL, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. *J Neurosurg* (2017) 126:319–29. doi: 10.3171/2015.12.JNS152443
66. Martin E, Muskens IS, Coert JH, Smith TR, Broekman MLD. Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis. *Neurooncol Pract* (2018) 6:1–10. doi: 10.1093/nop/npy025
67. Martin E, Coert JH, Flucke UE, Slooff W-BM, van de Sande MAJ, van Noesel MM, et al. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. *Pediatr Blood Cancer* (2019) 67:e28138. doi: 10.1002/pbc.28138
68. van Noesel MM, Orbach D, Brennan B, Kelsey A, Zanetti I, de Salvo GL, et al. Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. *Pediatr Blood Cancer* (2019) 66:e27833. doi: 10.1002/pbc.27833
69. Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. *Nat Genet* (2014) 46:1227–32. doi: 10.1038/ng.3095
70. Schaefer I-M, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. *Mod Pathol* (2016) 29:4–13. doi: 10.1038/modpathol.2015.134
71. Ghadimi MP, Young ED, Belousov R, Zhang Y, Lopez G, Lusby K, et al. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. *Clin Cancer Res* (2012) 18:2545–57. doi: 10.1158/1078-0432.CCR-11-2592
72. van IJzendoorn DGP, Suzhai K, Briaire-de Bruijn IH, Kostine M, Kuijjer ML, Bovee JVMG. Machine learning analysis of gene expression data reveals novel diagnostic and prognostic biomarkers and identifies therapeutic targets for soft tissue sarcomas. *PLoS Comput Biol* (2019) 15:e1006826. doi: 10.1371/journal.pcbi.1006826

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Martin, Acem, Grünhagen, Bovée and Verhoef. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.